CureVac

Clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA

Capitalization

$199.5

Close date

8/20/2020

Profitability

307.94%

About

Total Funding

$1.8B

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Number of employees

251 - 500

Headquarters

Tübingen, Baden-Wurttemberg, Germany